Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5478105 | 0.98 | TP53 (0.43) | TP53PKMMAPTMEN1KMT2A | |
| SCHEMBL10450411 | 0.98 | TP53 (0.43) | TP53PKMMAPTMEN1KMT2A | |
| SCHEMBL10471196 | 0.98 | TP53 (0.43) | TP53PKMMAPTMEN1KMT2A | |
| SCHEMBL1508100 | 0.95 | MAPT (0.44) | TP53PKMMAPTMEN1KMT2A | |
| SCHEMBL10902327 | 0.89 | MAPT (0.43) | TP53PKMMAPTMEN1KMT2A | |
| SCHEMBL7876219 | 0.87 | ARG1 (0.36) | MAPTKMT2ACYP2C9 | |
| SCHEMBL8773998 | 0.82 | ALOX5 (0.40) | TP53PKMMAPTMEN1KMT2A | |
| SCHEMBL8774071 | 0.81 | ALOX5 (0.42) | TP53MEN1KMT2AHTTALOX5 | |
| SCHEMBL17027427 | 0.81 | TP53 (0.41) | TP53PKMMAPTMEN1KMT2A | |
| SCHEMBL11310025 | 0.80 | POLB (0.39) | POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048335-B2 | Cholesteric liquid crystal composition | CHISSO CORPORATION (JP) | 2011-11-01 | — | — | US | disclosed |
| US-20100086506-A1 | CHOLESTERIC LIQUID CRYSTAL COMPOSITION | CHISSO CORPORATION (JP) | 2010-04-08 | — | — | US | disclosed |
| US-20020015804-A1 | LIQUID-CRYSTAL COMPOUNDS, LIQUID-CRYSTAL COMPOSITION CONTAINING THE SAME, AND LIQUID-CRYSTAL DISPLAY ELEMENT CONTAINING THE SAME | CHISSO CORPORATION (JP) | 2002-02-07 | — | — | US | disclosed |
| US-6174573-B1 | 3,4'-(HALO OR HALOGEN),4-((CYCLO)ALK(OXY)CARBONYLOXY)-DIPHENYLACETYLENE COMPOUNDS WHICH INCREASE THE N-I POINT (NEMATIC ANISOTROPY PHASE TRANSITION TEMPERATURE), AND THE DOUBLE REFRACTIVE INDEX | CITIZEN WATCH CO., LTD. (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0976703-A1 | LIQUID-CRYSTAL COMPOUNDS, LIQUID-CRYSTAL COMPOSITION CONTAINING THE SAME, AND LIQUID-CRYSTAL DISPLAY ELEMENT CONTAINING THE SAME | CHISSO CORPORATION (JP) | 2000-02-02 | — | — | EP | disclosed |
| US-5972244-A | INCREASE THE N-I POINT, DECREASE VISCOSITY, AND INCREASE DOUBLE REFRACTIVE INDEX OF A LIQUID CRYSTAL COMPOSITION WITHOUT AFFECTING THRESHOLD VOLTAGE | CITIZEN WATCH CO., LTD. (JP) | 1999-10-26 | — | — | US | disclosed |
| US-5478496-A | Media containing thiazole derivatives and thiadiazole derivatives and having a smectic liquid-crystalline phase | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-12-26 | — | — | US | disclosed |
| US-5348677-A | Electro-optical liquid crystal display element | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1994-09-20 | — | — | US | disclosed |
| US-5196140-A | ELECTRO-OPTICAL LIQUID CRYSTAL DISPLAY ELEMENT | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-03-23 | — | — | US | disclosed |
| US-4948790-A | Long-acting androgenic compounds and pharmaceutical compositions thereof | ARCHER SYDNEY (US) | 1990-08-14 | — | — | US | disclosed |
| EP-0152697-B1 | HETEROCYCLICALLY SUBSTITUTED ETHANES AND THEIR USE IN LIQUID CRYSTAL MATERIALS AND DEVICES | The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and (GB) | 1988-12-07 | — | — | EP | disclosed |
| US-4713197-A | Nitrogen-containing heterocyclic compounds | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1987-12-15 | — | — | US | disclosed |
| US-4698176-A | Heterocyclically substituted ethanes and their use in liquid crystal materials and devices | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1987-10-06 | — | — | US | disclosed |
| US-4642199-A | Novel liquid crystal compounds and liquid crystal compositions containing same | CHISSO CORPORATION (JP) | 1987-02-10 | — | — | US | disclosed |
| US-4632515-A | Heterocyclically substituted ethanes and their use in liquid crystal materials and devices | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1986-12-30 | — | — | US | disclosed |
| EP-0164721-A2 | Novel liquid crystal compound and liquid crystal composition containing same | Chisso Corporation (JP) | 1985-12-18 | — | — | EP | disclosed |
| EP-0152697-A1 | Heterocyclically substituted ethanes and their use in liquid crystal materials and devices | The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and (GB) | 1985-08-28 | — | — | EP | disclosed |
| US-4452718-A | Pyridazines | HOFFMANN-LA ROCHE INC. (US) | 1984-06-05 | — | — | US | disclosed |
| US-4419262-A | Pyridazines | HOFFMANN-LA ROCHE INC. (US) | 1983-12-06 | — | — | US | disclosed |
| US-4113647-A | ELECTRO-OPTIC DISPLAY DEVICE | THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100086506-A1 | CHOLESTERIC LIQUID CRYSTAL COMPOSITION | CYP46A1, NR1H3, NR1H4 | TP53 4139/4885PKM 4055/4885MAPT 1849/4885 |
| US-20020015804-A1 | LIQUID-CRYSTAL COMPOUNDS, LIQUID-CRYSTAL COMPOSITION CONTAINING THE SAME, AND LIQUID-CRYSTAL DISPLAY ELEMENT CONTAINING THE SAME | CXCR1, CCR1, CXCR2 | TP53 837/4885PKM 4357/4885MAPT 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.